Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
PR Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤Compugen to present UnigenX™ AI platform at PEGS Europe, November 18, 2026
- ➤UnigenX™ targets novel tumor-associated antigens for selective immune activation
- ➤Presentation focuses on T cell engagers and multispecific antibody combinations
- ➤Compugen’s COM701 is under evaluation in a randomized ovarian cancer trial
- ➤Gilead-licensed GS-0321 is being evaluated in a Phase 1 trial
Expert Statements
Roy Granit, Head of Computational Discovery at Compugen
“UnigenX™: AI-Powered Discovery Platform for Novel Tumor-Associated Antigens for Targeted Immune Activation”
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit PR Newswire
HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced an oral presentation at the 18(th) Annual Protein and Antibody Engineering Summit (PEGS) Europe, taking place November 16-19, 2026, in Lisbon, Portugal.
Get started
Create a free account to read the full story.